NEW YORK ( TheStreet) -- Shares of Keryx Biopharmaceuticals (Nasdaq: KERX) were gapping down Tuesday morning with an open price 11.5% lower than Monday's closing price. The stock closed at $4.94 Monday and opened today's trading at $4.37. The average volume for Keryx has been 1.1 million shares per day over the past 30 days. Keryx has a market cap of $218 million and is part of the health care sector and drugs industry. Shares are up 95.3% year to date as of the close of trading on Monday. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. TheStreet Ratings rates Keryx as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins. You can view the full Keryx Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.